ArticleAdvances in radiation oncology
The role of bone marrow and spleen irradiation in the development of acute hematologic toxicity during chemoradiation for esophageal cancer.
Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Consensus radiation therapy organ at risk constraints for NCTN trials in hematologic malignancies.Journal of the National Cancer Institute · 2026Article
- Clinical Considerations of Splenic Dose Constraints to Mitigate Radiation-Induced Lymphopenia.Cancer medicine · 2026Article
- Changes in splenic volumes following stereotactic ablative radiotherapy (SABR) to adrenal tumors.Clinical and translational radiation oncology · 2025Article
- Toxicity assessment following conventional radiation therapy and pulsed low dose rate radiation therapy: an in vivo animal study.Radiation oncology (London, England) · 2024Article
- The relationship between splenic dose and radiation-induced lymphopenia.Journal of radiation research · 2024Article
- Whole body irradiation with intensity-modulated helical tomotherapy prior to haematopoietic stem cell transplantation: analysis of organs at risk by dose and its effect on blood kinetics.Journal of cancer research and clinical oncology · 2023Article
- Splenic irradiation contributes to grade ≥ 3 lymphopenia after adjuvant chemoradiation for stomach cancer.Clinical and translational radiation oncology · 2022Article
- Monocyte programming by cancer therapy.Frontiers in immunology · 2022Review
- Bone marrow stromal cell therapy improves survival after radiation injury but does not restore endogenous hematopoiesis.Scientific reports · 2020Article
- A review of radiation-induced lymphopenia in patients with esophageal cancer: an immunological perspective for radiotherapy.Therapeutic advances in medical oncology · 2020Review
- Bystander Effects and Unintended Consequences: Time to Include the Spleen in Radiation Therapy Planning.Frontiers in oncology · 2020Article
- Radiomitigation by Melatonin in C57BL/6 Mice: Possible Implications as Adjuvant in Radiotherapy and Chemotherapy.In vivo (Athens, Greece)Article
- Assessing the Spleen as an Organ at Risk in Radiation Therapy and Its Relationship With Radiation-Induced Lymphopenia: A Retrospective Study and Literature Review.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to determine the impact of splenic and thoracic bone marrow irradiation on hematologic toxicity in the setting of chemoradiation therapy for esophageal cancer. METHODS AND MATERIALS: We analyzed 60 patients with carcinoma of the distal esophagus or gastroesophageal junction who received concurrent chemoradiation in the preoperative or definitive setting. Dosimetric and volumetric parameters were calculated for the spleen, thoracic spine, and posterior ribs. The primary endpoint was grade ≥3 hematologic toxicity (HT3+). Associations were assessed using logistic and linear regression models.
resultsTwenty-one patients (35%) experienced HT3+, including 18 patients with leukopenia and 5 with thrombocytopenia. Higher spleen V5-V20 was correlated with a lower risk of HT3+ on multivariable analysis (odds ratio: 0.83 per 10 cm
conclusionsA greater decrease in spleen size after radiation therapy and a higher spleen V5-V20 were independently associated with a lower risk of severe hematologic toxicity. Splenic irradiation may mitigate leukopenia associated with chemoradiation therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.